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A B S T R A C T
Leber congenital amaurosis (LCA) is an inherited retinal dystrophy that is characterized by severe visual impairment in early infancy. We generated a human induced
pluripotent stem cell (hiPSC) line, DKHi090-A, from peripheral blood mononuclear cells (PBMCs) of a patient with LCA, by using a Sendai virus-based gene delivery
system. We confirmed that DKHi090-A has a nicotinamide mononucleotide adenyltransferase 1 (NMNAT1) mutation and normal karyotype. DKHi090-A line is
pluripotent and is capable of multilineage differentiation. This cell line is registered and is available at the National Stem Cell Bank, Korea National Institute of
Health.
Resource table
Unique stem cell line i-
dentifier
DKHi090-A
Alternative name(s) of
stem cell line
DKH090i-A
Institution Korea National Institute of Health
Contact information of
distributor
Soo Kyung Koo, skkoo@nih.go.kr
Type of cell line iPSC
Origin Human
Additional origin info Applicable for human iPSC
Age: 1 year
Sex: female
Ethnicity if known: Korean
Cell Source Peripheral blood mononuclear cells
Clonality Clonal
Method of reprogram-
ming
Transgene free Sendai virus
Genetic Modification Yes
Type of Modification Spontaneous mutation
Associated disease Leber congenital amaurosis
Gene/locus NM 022787.3(NMNAT1): c.709C>T/Chr1:
9982570(GRCh38)
Method of modification N/A
Name of transgene or r-
esistance
N/A
Inducible/constitutive s-
ystem
N/A
Date archived/stock da-
te
June 2018
Cell line repository/ba-
nk
Korea National Stem Cell Bank(KSCB)
Ethical approval Yonsei University Health System, Severance Hospital,
Institutional Review Board(IRB) approval obtained (IRB
No. 4-2016-1158)
IRB approval obtained (IRB No. 2017-03-05-C-A)
1. Resource utility
Leber congenital amaurosis (LCA) is a severe retinal disorder (den
Hollander et al., 2008). Various genetic mutations have been reported
in patients with the disease. However, the mechanism underlying ni-
cotinamide mononucleotide adenyltransferase 1 (NMNAT1)(Alias:
LCA9) mutation-induced LCA is poorly understood. This hiPSC line
might serve as an effective disease model to study LCA9 pathogenesis.
2. Resource details
To date, mutations in 26 genes have been reported as the cause of
Leber congenital amaurosis (LCA). These genes are mostly involved in
the phototransduction cascade in retinal photoreceptor cells. However,
mutations in nicotinamide mononucleotide adenyltransferase 1
(NMNAT1) (Alias: LCA9) gene, which is involved in NAD+ biosynth-
esis, lead to severe macular coloboma in infancy (Siemiatkowska et al.,
2014). Although NMNAT1 activity is critical for normal cellular meta-
bolism in most tissues, changes in phenotype have been reported only
in the retina. Hence, study of its functional role in the retina is im-
portant for understanding the pathogenesis of LCA9 and designing
novel drugs for retinal dystrophy. The patient was a 6-month-old girl
who was under evaluation in our institution, for poor eye contact. The
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Fig. 1. Characterization of DKHi090-A cell line.
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pregnancy and birth were uneventful, and she was born as a normal
healthy baby. At the age of 3 months, wandering eye movement was
noted, and she was referred to our clinic. The pupil was sluggish, re-
active to light, and could not maintain fixation. Dilated fundus ex-
amination showed macular coloboma retinal degeneration in both the
eyes. Neurological examination was normal. Magnetic resonance ima-
ging for the brain was also normal. Targeted panel sequencing analysis
revealed NMNAT1 c.709C>T:p.Arg237Cys homozygous mutation. This
variant was previously reported in LCA patients. We generated the
hiPSC line, DKHi090-A, by reprogramming the PBMCs of the LCA pa-
tient under study by using the Sendai virus-based gene delivery system.
The generated line showed a typical hiPSC morphology with a large
nuclear to cytoplasmic ratio (Fig. 1A). Moreover, our G-banding ana-
lysis showed a normal karyotype (46, XX) in these cells (Fig. 1B). All
reprogramming factors were found to be silenced in the DKHi090-A
hiPSC line (Fig. 1C). The pluripotency of the generated hiPSC line was
characterized by immunocytochemistry analysis using pluripotency
markers such as OCT4, SSEA4, Tra-1-60, and Tra-1-81 (Fig. 1D). We
also confirmed pluripotency at the mRNA level by using TaqMan® ex-
pression probes. The results were analyzed based on the embryonic
stem cell line, H9 (Fig. 1E). The disease-causing mutation (C709T) was
confirmed in the DKHi090-A hiPSC line (Fig. 1F). To determine the
differentiation ability, we generated embryoid bodies from the hiPSC
line (Fig. 1G). Using Taqman® expression probes, we confirmed that
these embryoid bodies expressed all three germ layer markers, PAX6
(ectoderm), T (mesoderm), and HNF3-β (endoderm) (Fig. 1H). Short
tandem repeat (STR) analysis was performed on DKHi090-A and the
donor cells. Sixteen allele loci of DKHi090-A matched with those of the
donor cells. Detailed information on STR analysis is presented in Sup-
plementary data. DKHi090-A was free from mycoplasma contamination
(Supplementary Fig. 1) (Table 1).
3. Materials and methods
3.1. Isolation of PBMCs
PBMCs were isolated using SepMate (Stemcell Technologies,
15450), according to the manufacturer's instructions. Briefly, the den-
sity gradient medium was added to the SepMate tube, following which
the diluted sample was added to the tube. The tube was then cen-
trifuged at 1200 g for 10 min at room temperature. The topmost layer
was then poured off into a new tube and washed twice with PBS.
3.2. Reprogramming and hiPSC maintenance
Human iPSCs were generated by reprogramming PBMCs using a
CytotuneiPS™-iPS 2.0 Sendai Reprogramming Kit (Life Technologies,
A16518), according to the manufacturer's protocol (Fusaki et al., 2009).
Obtained clones were cultured onto vitronectin (Gibco, A14700) coated
plates in TeSR™-E8™ medium (Stemcell Technologies, 05990) at 37 ℃
in a 5% CO2 atmosphere. The culture medium was changed every day.
Cells were passaged using 0.5 mM EDTA (Invitrogen, 15575-020) with
10 μM Y-27632 (Sigma, Y-0503).
3.3. Karyotyping
The cultured cells were treated with colcemid for 45 min and then
harvested in hypotonic solution with fixative, following which the
metaphase slides were prepared. After Giemsa-trypsin banding, the
karyotype was analyzed according to the International System for
Human Cytogenetic Nomenclature using the standard GTG-banding
method.
3.4. Detection of the reprogramming vector
Total RNA was isolated using a Maxwell® RSC simplyRNA Cells Kit
(Promega, AS1390), and cDNA was synthesized by reverse transcription
using RNA to cDNA EcoDry Premix (Clontech, 639543). hiPSCs at
passage 2 were used as a positive control. PCR (C1000 Touch Thermal
Cycler, BIO-RAD) was performed as follows: 95 ℃ for 5 min, 95 ℃ for
30 s, 60 ℃ for 30 s, 72 ℃ for 30 s (32 cycles), 72 ℃ for 5 min, and
maintained at 4 ℃. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was amplified concurrently and used as an internal control. A
negative control was included in all runs with all of the same compo-
nents except the template to detect contamination with nucleic acids.
3.5. Mutation sequencing
Genomic DNA was isolated using a Maxwell® RSC Blood DNA Kit
(Promega) and sent to Cosmogenetech (Seoul, Korea) with designed
primers. The control cell line used here was the KSCBi002-B, which is
already registered in the hPSCreg.
3.6. Immunocytochemistry
Cells were fixed using 4% paraformaldehyde (Wako, 163-20145) for
20 min, blocked with 5% bovine serum albumin (Sigma-Aldrich,
A9647) with 0.25% Triton X (Sigma-Aldrich, A8787), and incubated
with primary antibodies for Oct3/4, SSEA4, Tra-1-60, and Tra-1-81
(Table 2). Images were acquired using a fluorescence microscope (Axio
Imager A2, Carl Zeiss). Scale bars represent 200 µm.
Table 1
Characterization and validation.
Classification Test Result Data
Morphology Photography Normal Fig. 1 panel A
Phenotype Immunocytochemistry OCT4, SSEA4, Tra-1-60 and Tra-1-81 Fig. 1 panel D
Real-time PCR NANOG, OCT4, SOX2, TERT, TDGF1, DNMT3B, GABRB3, GDF3 and
REX1
Fig. 1 panel E
Genotype Karyotype (G-banding) and resolution 46XX, Resolution 500 Fig. 1 panel B
Identity Microsatellite PCR(mPCR) Not performed Not performed
STR analysis Tested 16 loci, all matched STR analysis
Mutation analysis (IF APPLICABLE) Sequencing Homozygous Fig. 1 panel F
Southern Blot OR WGS Not performed Not performed
Microbiology and virology Mycoplasma Mycoplasma testing by RT-PCR negative Supplementary figure 1
Differentiation potential Embryoid body formation Paired box 6 (PAX6) for ectoderm, Brachyury (T) for mesoderm and
Hepatocyte nuclear factor-3 beta (HNF-3β) for endoderm
Fig. 1 panel G and H
Donor screening (OPTIONAL) HIV 1 + 2 Hepatitis B, Hepatitis C Not performed Not performed
Genotype additional info
(OPTIONAL)
Blood group genotyping Not performed Not performed
HLA tissue typing Not performed Not performed
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3.7. Real-time PCR analysis
Real-time PCR (QuantStudio™6 Flex, Applied Biosystems) was per-
formed using Taqman® Gene Expression Master Mix (Applied
Biosystems, 4369510). PCR conditions were as follows: 50 ℃ for 2 min,
95 ℃ for 10 min at the hold stage, and 95℃ for 15 s, 60℃ for 1 min at
the PCR stage for 40 cycles. All quantitative gene expressions were
normalized to the expression level of GAPDH. The probes used are
listed in Table 2.
3.8. In vitro differentiation into the three germ layers
To determine the capacity of the hiPSCs to differentiate into the
three germ layers, we induced embryoid bodies using hiPSCs harvested
by dispase (Gibco, 17105-041). The culture medium for embryoid
bodies was DMEM/F12 (Gibco, 11320-082) supplemented with 20%
Knockout Serum Replacement (Gibco, 10828-028), 0.1 mol/L Minimal
Essential Media non-essential amino acids solution (Gibco, 11140-050),
0.1 mmol/L 2-mercaptoethanol (Gibco, 21985-023), 1% (v/v) anti-
biotic-antimycotic (Gibco, 15240-112), and MycoZap plus-PR (Lonza,
VZA2021). The culture medium was changed every other day. The
embryoid bodies were harvested after 14 days and real-time PCR ana-
lysis was conducted for the three germ layer. The probes used are listed
in Table 2.
3.9. STR analysis
STR analysis of the generated hiPSCs and parental cells was per-
formed using a PowerPlex 16 System (Promega) to detect 16 loci at the
Samkwang Medical Laboratories (Seoul, Korea).
3.10. Mycoplasma test
The Mycoplasma test of the cell culture medium was performed
using a PCR Mycoplasma Detection Set (TAKARA, 6601) according to
the manufacturer's protocol. Briefly, we mixed the cell culture medium
with the 1st PCR reaction mixture and performed the 1st PCR. The 1st
PCR product was added into the 2nd PCR reaction mixture and the 2nd
PCR was performed. Gel electrophoresis was performed using the pro-
ducts from the 1st and 2nd PCRs to confirm the presence of myco-
plasma.
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Table 2
Reagents details.
RRID Requirement for antibodies: use http://antibodyregistry.org/ to retrieve RRID for antibodies and include ID in table as shown in examples.
Antibodies used for immunocytochemistry/flow-citometry
Antibody Dilution Company Cat # and RRID
Pluripotency Marker Rabbit anti-OCT3/4 1:200 Santa Cruz Biotechnology Cat# sc-9081, RRID:AB_2167703
Pluripotency Marker Mouse anti-SSEA4 1:200 Millipore Cat# MAB4304, RRID:AB_177629
Pluripotency Marker Mouse anti-TRA-1-60 1:200 Millipore Cat# MAB4360, RRID:AB_2119183
Pluripotency Marker Mouse anti-TRA-1-81 1:200 Millipore Cat# MAB4381, RRID:AB_177638
Secondary antibody Anti-rabbit IgG(H+L) Fluorescein conjugated 1:500 Vector Laboratories Cat# FI-1000, RRID:AB_2336197
Secondary antibody Anti-mouse IgG(H+L) Fluorescein conjugated 1:500 Vector Laboratories Cat# FI-2000, RRID:AB_2336176
Primers
Target Forward/Reverse primer (5′-3′)
Sendai virus test(RT-PCR) SeV GGATCACTAGGTGATATCGAGC/ ACCAGACAAGAGTTTAAGAGATATGTATC
Sendai virus test(RT-PCR) KOS ATGCACCGCTACGACGTGAGCGC/ ACCTTGACAATCCTGATGTGG
Sendai virus test(RT-PCR) Klf4 TTCCTGCATGCCAGAGGAGCCC/ AATGTATCGAAGGTGCTCAA
Sendai virus test(RT-PCR) c-Myc TAACTGACTAGCAGGCTTGTCG/ TCCACATACAGTCCTGGATGATGATG
Targeted mutation analysis/sequencing NMNAT1, 709C>T GTTACTCGGGCTGGAAATGA/ CCCAAATGGGAAGTCTGAAA
House-Keeping Gene(RT-PCR) GAPDH CATGTTCGTCATGGGTGTGAA/ GGACTGTGGTCATGAGTCCTT
Pluripotency Marker (qPCR) NANOG Hs02387400-g1 (Taqman® probe ID)
Pluripotency Marker (qPCR) OCT4 Hs00742896-s1 (Taqman® probe ID)
Pluripotency Marker (qPCR) SOX2 Hs00602736-s1 (Taqman® probe ID)
Pluripotency Marker (qPCR) TERT Hs00162669-m1 (Taqman® probe ID)
Pluripotency Marker (qPCR) TDGF1 Hs02339499-g1 (Taqman® Probe ID)
Pluripotency Marker (qPCR) DNMT3B Hs00171876-m1 (Taqman® Probe ID)
Pluripotency Marker (qPCR) GABRB3 Hs00241459-m1 (Taqman® Probe ID)
Pluripotency Marker (qPCR) GDF3 Hs00220998-m1 (Taqman® Probe ID)
Pluripotency Marker (qPCR) REX1 Hs00399279-m1 (Taqman® Probe ID)
Differentiation Marker (qPCR) PAX6 Hs00240871-m1 (Taqman® Probe ID)
Differentiation Marker (qPCR) T (Brachyury) Hs00610080-m1 (Taqman® Probe ID)
Differentiation Marker (qPCR) HNF-3β Hs00232764-m1 (Taqman® Probe ID)
House-Keeping Gene (qPCR) GAPDH Hs999999905-m1 (Taqman® Probe ID)
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